Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept studyFederica Miglietta, Valentina Guarneri, G. Griguolo et al.|ESMO Open|2024Cited by 7
A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter studyFederica Miglietta, M.V. Dieci, M. Ragazzi et al.|European Journal of Cancer|2022Cited by 0
178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent diseaseFederica Miglietta, Maria Vittoria Dieci, Lorenzo Nicolè et al.|Annals of Oncology|2024Cited by 0